Ocular Therapeutix (NASDAQ:OCUL) Shares Down 7.2% – Time to Sell?

10 Apr 2026, 18:44 by Mitch Edgeman · The Markets Daily

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report)’s stock price dropped 7.2% during mid-day trading on Friday . The company traded as low as $8.71 and last traded at $8.6350. Approximately 925,715 shares were traded during trading, a decline of 85% from the average daily volume of 6,029,468 shares. The stock had previously closed at $9.30.

Wall Street Analyst Weigh In

OCUL has been the subject of a number of research reports. William Blair reiterated an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Citigroup reiterated an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Chardan Capital restated a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a research note on Wednesday, February 18th. Royal Bank Of Canada restated an “outperform” rating and issued a $30.00 price target on shares of Ocular Therapeutix in a research note on Thursday, February 5th. Finally, Wall Street Zen downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.78.

Get Our Latest Stock Analysis on Ocular Therapeutix

Ocular Therapeutix Stock Performance

The company has a quick ratio of 15.32, a current ratio of 15.39 and a debt-to-equity ratio of 0.11. The stock has a 50 day simple moving average of $8.80 and a two-hundred day simple moving average of $10.84. The stock has a market capitalization of $1.91 billion, a P/E ratio of -6.08 and a beta of 0.95.

Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The company had revenue of $13.25 million during the quarter, compared to the consensus estimate of $16.13 million. During the same period in the previous year, the company posted ($0.29) EPS. The firm’s revenue for the quarter was down 22.4% compared to the same quarter last year. On average, equities analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, Director Richard L. Md Lindstrom bought 60,229 shares of Ocular Therapeutix stock in a transaction dated Friday, February 20th. The stock was bought at an average cost of $7.66 per share, for a total transaction of $461,354.14. Following the purchase, the director owned 246,933 shares of the company’s stock, valued at $1,891,506.78. The trade was a 32.26% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Nadia Waheed sold 7,863 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $9.04, for a total value of $71,081.52. Following the transaction, the insider owned 318,417 shares of the company’s stock, valued at $2,878,489.68. This represents a 2.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 197,221 shares of company stock worth $1,754,805 in the last three months. 2.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in OCUL. Steward Partners Investment Advisory LLC boosted its stake in shares of Ocular Therapeutix by 124.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,242 shares during the period. Rockefeller Capital Management L.P. bought a new stake in Ocular Therapeutix in the 4th quarter valued at $31,000. Hilton Head Capital Partners LLC bought a new stake in Ocular Therapeutix in the 4th quarter valued at $42,000. Atlas Capital Advisors Inc. bought a new stake in Ocular Therapeutix in the 4th quarter valued at $61,000. Finally, KBC Group NV bought a new stake in Ocular Therapeutix in the 4th quarter valued at $78,000. 59.21% of the stock is currently owned by institutional investors.

About Ocular Therapeutix

(Get Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.